Ryan Daniels • William Blair

Answer

CEO Jeff Tangney confirmed that the company plans to follow a similar "freemium" to enterprise model as it did with the Dialer. He noted that they have already been approached by clients about Scribe and that the Pathway acquisition demonstrated a proven model of physicians paying for premium clinical tools, signaling a clear long-term opportunity for enterprise subscription revenue.

Ask Fintool Equity Research AI

Answer

CFO Anna Bryson explained that the integrated programs, which start in January with the first available module, could lead to a more consistent year-over-year revenue curve. CEO Jeff Tangney added that Doximity has over 60% of all NPs as members and that they are highly engaged with workflow tools like AI-powered letter writing and faxing, representing a key growth area.

Ask Fintool Equity Research AI

Answer

CEO Parth Mehrotra confirmed this is a good observation, stating that Privia's track record and multifaceted approach are leading to more productive, forward-leaning conversations with payers. He emphasized that Privia's model, which involves sharing risk with both payers and doctors and avoiding unsustainable full-risk models, is seen as a stable, reliable way for payers to build density and achieve results. This success in one state helps replicate favorable contract terms, including care management fees, in new geographies.

Ask Fintool Equity Research AI

Answer

CEO Jay Mazelsky explained that international investments aim to increase commercial density, as coverage per rep is much higher than in the U.S. The modest U.S. expansion is to support a growing product portfolio. On CancerDx, he reported strong enthusiasm, with initial usage weighted more toward 'aid in diagnosis' as veterinarians validate the test's performance. He noted that a growing number of practices are incorporating it into wellness screens and that 15% of submissions are from competitive lab customers.

Ask Fintool Equity Research AI

Answer

President and CEO Jay Mazelsky explained the international investments aim to increase commercial density, as higher call frequency drives diagnostic usage. The modest U.S. expansion supports the growing product portfolio. Regarding CancerDx, he noted strong enthusiasm, with usage initially weighted toward "aid in diagnosis" as vets test its performance. He was pleased that 15% of submissions are from competitive lab customers.

Ask Fintool Equity Research AI

Answer

CEO Matt Hawkins stated that Waystar's win rates remain strong and consistent with previously disclosed figures. He noted a level of unrest in the competitor's client base, which, combined with Waystar's strong pipeline and bookings, presents an opportunity for the company to be a significant share gainer.

Ask Fintool Equity Research AI

Answer

CEO Matt Hawkins agreed this is a beneficial trend that Waystar is beginning to see. He explained that generative AI allows for the automation of high-volume, low-complexity tasks, enabling providers to bring functions back in-house that they previously had to outsource. He cited examples like denial prevention and automated appeal letter generation, which reduce staff time and improve outcomes. Hawkins believes this trend will expand Waystar's addressable market by replacing expensive outsourced services with efficient software and AI.

Ask Fintool Equity Research AI

Answer

CEO Matthew Hawkins responded that while RFPs are more complex, particularly regarding cybersecurity, sales cycles are not extending beyond normal timeframes. He identified claim denials and managing higher patient volume with limited staff as key pain points from the conference, which directly inform R&D priorities, like generative AI, and the company's disciplined M&A approach.

Ask Fintool Equity Research AI

Answer

Chief Communications Officer Matthew McKee explained that the new business pipeline is evenly split between EVS and dietary, but the preference remains to lead with EVS and then cross-sell dining, a strategy with significant runway as dining penetration is still under 50% of the EVS base. He added that the education segment, while less than 5% of revenue, continues to show positive returns and remains a commitment for future growth, complementing the core business strategy.

Ask Fintool Equity Research AI

Answer

Executive Seth Blackley described the navigation solution as a key differentiator in a strong selling environment. He estimated it could increase the total savings opportunity by 10-20% by engaging patients and addressing Part A medical costs, which complements the traditional focus on Part B. He believes this will enhance sales conversions and drive value.

Ask Fintool Equity Research AI

Answer

CFO John Johnson stated the narrowing was driven by a focus on core operations. He quantified the risk reduction by noting a 200 basis point trend uptick that now impacts EBITDA by $9 million would have been a $20-$25 million impact previously. He also confirmed that the $10 million investment in 2025 followed by a $20 million benefit in 2026, creating a $30 million net swing, was 'approximately correct' but not official guidance.

Ask Fintool Equity Research AI

Answer

John Johnson confirmed the analyst's understanding of the rate increase mechanics was correct. He clarified that the 50% cancer prevalence increase was an extreme example from one market in August compared to the prior year's average, but noted that a broader, significant increase in prevalence is being observed across the business.

Ask Fintool Equity Research AI

Answer

CEO Dave Bourdon stated it is too early to comment on the EHR project's cost or timeline but noted its goal is to enhance clinician and patient experiences and drive efficiency. He described the digital patient check-in tool as a 'game changer' for automating collections for virtual visits, which has been a primary driver of the improved DSO of 38 days.

Ask Fintool Equity Research AI

Answer

CEO Steven Sell projected 30,000 to 45,000 new members for 2026, with a focus on existing geographies, but noted the main focus is on a rich pipeline for the 2027 class. CFO Jeffrey Schwaneke explained the negative charge was a true-up and reversal of an accrual for annual wellness visits.

Ask Fintool Equity Research AI

Answer

CEO Steven Sell clarified the fee is paid by the payor directly to the 50-50 partnership agilon operates with its physicians. He confirmed there is upside potential through performance incentives, particularly for quality. The model is a 'glide path' where the transition to full risk is discussed toward the end of year one, with the expectation to move to full risk over time.

Ask Fintool Equity Research AI

Answer

CEO John Kao clarified that the focus is on leveraging their proven, differentiated care management capabilities for complex populations, which is performing well both in and out of California. He confirmed that the company is actively planning for new market entries in 2026 and initiating processes for 2027 launches, all funded by operating cash. While a services business is a future possibility, the approach remains disciplined and thoughtful.

Ask Fintool Equity Research AI

Answer

CEO John Kao explained that the company is deepening its "ground game" by investing in provider operations and scaling its Care Anywhere clinical model to improve visibility and control. He attributed the strong membership growth to a disciplined bid strategy that leveraged advantages in Star ratings and the V28 risk model, combined with prior investments in the member experience to boost retention.

Ask Fintool Equity Research AI

Answer

CEO Chaim Indig stated that scale is a key requirement from the early stages of product development, so products are typically scalable upon public discussion. He added that the entry of larger players has been a net positive, as it raises market awareness and Phreesia's close rates have improved.

Ask Fintool Equity Research AI

Answer

Executive Balaji Gandhi stated that the company expects to continue gaining leverage from its sales and marketing spend, which has been stable for around 11 quarters. CEO Chaim Indig clarified that MEDITECH is a reseller for a small piece of Phreesia's technology, but the alliance primarily facilitates direct sales of a broader product suite to MEDITECH clients, with integration rolling out over the coming years.

Ask Fintool Equity Research AI

Answer

CEO Robert Frist stated that the HLX product is live, priced, and available for sale, with the sales team now trained. He anticipates initial sales in the first half of 2025, with an acceleration in the second half following successful pilots. Regarding interoperability, Frist noted that while cross-selling is already a strength, the technology-enabled benefits are expected to manifest more significantly in the second half of the year as they work with key customers to adopt the full 'suite of suites'.

Ask Fintool Equity Research AI

Answer

CEO Waleed Hassanein agreed that high penetration can lead to short-term susceptibility, as seen in Q3, but emphasized the company is 'just getting started' and stands by its 10,000 transplants by 2028 goal. CFO Stephen Gordon reaffirmed that a mid-60s long-term gross margin is still the goal, contingent on gaining service efficiencies by maximizing the use of their owned aircraft.

Ask Fintool Equity Research AI